Mohanraj Nehru
1 
, Prasanth Subramanian
1 , Vinothkumar Ganesan
2 , Rajiv Janardhanan
1 , Venkataraman Prabhu
1* 1 Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Tamil Nadu, India
2 Department of Medical Research, Dr. V Balaji Dr. V Seshiah Diabetes Care and Research Institute, Aminjikarai, Tamil Nadu, India
Abstract
Endocrine society has evidence that plastics can disrupt the endocrine system to cause severe diseases in humans and animals. However, plastics are still used in a variety of models for their applications. The overproduction of plastics simultaneously increases health hazards in human and animal living society. The pancreas is an endocrine system to produces insulin to maintain the glucose level in the blood when that insulin level resists or does not synthesize causing diabetes mellitus. It is one of the highest prevalence diseases occurred in worldwide. Sirtuin-1 is a protein involved in glucose homeostasis and it regulates insulin action. In the human body, hampered the level of insulin, sirtuin-1, and glucose cause diabetes and its vascular complications. Furthermore, many researchers evidenced that the endocrine disruptor of bisphenol A (BPA) causes diabetes mellitus and its vascular complications. Nevertheless, the biological pathway is unclear. This review discusses the linkage between the endocrine disruptor of BPA and diabetes and explores Sirtuin-1 mediated BPA-induced diabetic vascular complications.
Implication for health policy/practice/research/medical education:
The endocrine disruptor BPA has a possible mechanism to decrease the sirtuin protein to develop diabetes-associated vascular complications. We explored the possible mechanism of sirtuin-induced diabetes and related vascular complications with the impact of BPA.
Please cite this paper as: Nehru M, Subramanian P, Ganesan V, Janardhanan R, Prabhu V. Bisphenol A instigates diminished sirtuin-1 mediated vascular complications in type 2 diabetes mellitus. J Nephropharmacol. 2024;13(2):e10531. DOI: 10.34172/npj.2023.10531.